Multinational companies have more drugs for PVA

The total number of negotiations between 5 and 8 consecutive countries in Korea

Rep. Lee Jong-sung said, "There is no overall reverse discrimination, but there must be a motive for the development of new domestic drugs"

The NHIS made an official position that it cannot accept the criticism that new domestic drugs are being reversely discriminated within the PVA.

 

After the parliamentary audit of the National Assembly's Health and Welfare Committee on the 15th, The NHIS replied, "It cannot be regarded as reverse discrimination in domestic new drugs," when asked about reverse discrimination by People Power Party lawmaker Lee Jong-sung.

 

For this reason, as a result of analyzing drugs applied more than three times in a row since the reorganization of the PVA system in 2014, seven drugs were included in the case of "Type Ka and Na" and six drugs in the case of "Type Da." However, among them, only six types of drugs (type Da) were domestic, and all of the other drugs (type Da) and seven drugs (type Ka and type Na) were from multinational companies.

 

Eight multinational companies had PV negotiations more than three times in a row.

 

In addition, in the case of items that have been cut more than three times, the price has changed due to drug prices and changes in the alternative drug market.

 

The NHIS selected 14,888 drugs as targets for monitoring drug analysis for negotiations on type Da in April this year.

 

Among them, 14,097 drugs from domestic pharmaceutical companies and 791 drugs from multinational pharmaceutical companies were applied, and the final number of drugs subject to negotiation was 55 (0.39%) from domestic pharmaceutical companies and 4 (0.51%) from multinational pharmaceutical companies.

 

Although domestic new drugs seem to be overwhelmingly subject to PVA negotiations, multinational companies are higher when calculating the ratio selected for negotiation.

 

The NHIS explained, "PVA is a system that cuts the upper limit through drug price negotiations between the NHIS and pharmaceutical companies when drug costs increase to a certain level, and the rate of increase in claims affects insurance finances." The NHIS emphasized, "Drugs subject to continuous drug price cuts through PVA continue to affect finances." Rep.

 

Lee Jong-sung also said in the data, "In the case of multinational history, most of them go through PVA in Type Ka and Na, and most of the domestic pharmaceutical companies in Type Da are applied, so it is understood that there is no reverse discrimination overall." Rep.

 

Lee said, "New drugs developed by multinational pharmaceutical companies and entering the domestic market are also subject to PVA measures, but domestic new drugs seem to have been repeatedly cut by PVA." "The government is creating a structure that cuts prices when sales of drugs that have a positive impact on health insurance finances," he said, urging the promotion of motivation for the development of new domestic drugs.

 

The NHIS said, "There was a preferential policy for new domestic drugs, but the related system was changed due to the Korea-U.S.

 

FTA trade dispute," adding, "As soon as the MOHW comes up with research services on preferential measures for domestic pharmaceutical companies, we will review them."